Researchers discover gene that permanently stops cancer cell proliferation
August 1, 2012 | MedicalXpress
Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs. This study illustrates an unprecedented finding, that artificially activating Chk1 alone is sufficient to kill cancer cells.
“We have identified a new direction for cancer therapy and the new direction is leading us to a reduction in toxicity in cancer therapy, compared with chemotherapy or radiation therapy,” said Dr. Zhang, assistant professor, Department of Pharmacology at the School of Medicine, and member of the university’s Case Comprehensive Cancer Center. “With this discovery, scientists could stop the proliferation of cancer cells, allowing physicians time to fix cells and genetic errors.” While studying the basic mechanisms for genome integrity, Dr. Zhang’s team unexpectedly discovered an active mutant form of human Chk1, which is also a non-natural form of this gene. This mutation changed the protein conformation of Chk1 from the inactive form into an active form. Remarkably, the research team discovered that when expressed in cancer cells, this active mutant form of Chk1 permanently stopped cancer cell proliferation and caused cell death in petri dishes even without the addition of any chemotherapeutic drugs. The biggest advantage of this potential strategy is that no toxic chemotherapeutic drug is needed to achieve the same cancer killing effect used with a combination of Chk1 inhibitors and chemotherapeutic drugs. Cells respond to DNA damage by activating networks of signaling pathways, termed cell cycle checkpoints. Central to these genome pathways is the protein kinase, called Chk1. Chk1 facilitates cell survival, including cancer cells, under stressful conditions, such as those induced by chemotherapeutic agents, by placing a temporary stop on the cell cycle progression and coordinating repair programs to fix the DNA errors. It has long been suggested that combining Chk1 inhibition with chemotherapy or radiotherapy should significantly enhance the anticancer effect of these therapies. This idea has serves as the basis for multiple pharmaceutical companies searching for potential Chk1 inhibitors that can effectively combine with chemotherapy in cancer therapy. To date, no Chk1 inhibitor has passed the clinical trial stage III . This led Dr. Zhang’s team to look for alternative strategies for targeting Chk1 in cancer therapy. Future research by Dr. Zhang and his team will consider two possible approaches to artificially activating Chk1 in cancer cells. One possibility is to use the gene therapy concept to deliver the active mutant form of Chk1 that the team discovered, into cancer cells. The other is to search for small molecules that can induce the same conformational change of Chk1, so that they can be delivered into cancer cells to activate Chk1 molecules. The consequence of either would be permanent cell proliferation inhibition and cancer. This study is published in Cancer Research.
This study is published in Cancer Research.
Journal reference: Cancer Research
Provided by Case Western Reserve University
School of Medicine researchers discover gene that permanently stops cancer cell proliferation
Imagine curing cancer without nausea, hair loss, swelling or any of the other maladies that can accompany chemotherapy or radiation.
This week researchers at Case Western Reserve University School of Medicine took an extraordinary step toward realizing that remarkable vision.
And, as so often happens in the annals of scientific discovery, their breakthrough came almost by accident.
Youwei Zhang and his colleagues stumbled upon the potential cancer killer while studying the basic mechanisms of a particular genome. In the process, they found a mutated form of a gene known as Chk1 which, when activated, proved lethal to cancer cells. Simply stopping the cells from multiplying en masse would have represented an enormous victory in itself. But this mutant gene also knocked off the diseased cells already in existence.
“We have identified a new direction for cancer therapy,” said Zhang, an assistant professor of pharmacology and member of the university’s Case Comprehensive Cancer Center (CCCC). “With this discovery, scientists could stop the proliferation of cancer cells, allowing physicians time to fix cells and genetic errors.”
Zhang and two postdoctoral fellows in pharmacology and at the CCCC, Jingna Wang and Xiangzi Han, published their findings in the Aug. 1 edition of the journal Cancer Research. They started looking at Chk1 because researchers long have been convinced the gene could enhance dramatically the ability of chemotherapy or radiation to help cancer patients. While multiple scientists have pursued this hybrid approach, none have managed to develop a product with the efficacy so many anticipated. In light of these difficulties, Zhang and his team elected to start anew with Chk1 itself. Now that they have realized such success on cells within petri dishes, they want to explore additional ways to activate Chk1 within cancer cells. One possibility is to use gene therapy to deliver the active mutant form of Chk1 into cancer cells. The other is to find molecules that can prompt the mutation within Chk1 cells already present.
The research to date received support from the National Cancer Institute.
Tracing Knowledge Notification | Ειδοποίηση Στα ίχνη της Γνώσης
of the original post, out of respect to the source and readers.
Please follow the link for references and more informations.
της πρωτότυπης δημοσίευσης με σεβασμό στην πηγή και στους αναγνώστες.
Παρακαλώ επισκεφθείτε τον σύνδεσμο για περισσότερες πληροφορίες.